Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing

Concerning clinical utility and validity, there is high variability between the effectiveness and - ultimately - usefulness, of high-density genotyping arrays versus genome-scale sequencing when considering large numbers of individuals. Though "not well-suited to clinical genetics applications seeking to identify novel disease-associated variants, high throughput genome-wide array technology can still provide the capacity to simultaneously assess essentially all single nucleotide polymorphisms (SNPs) of known functional importance in the human genome", which is sufficient for most pharmacogenomic applications. Continue to the original primary literature below to learn more about the landscapes of cost, translation and efficiency as they relate to the individual and their point-of-care medical provider.

Read More Here